Tuvia Shoham - Kamada Independent Director
KMDA Stock | ILA 1,984 14.00 0.71% |
Director
Mr. Tuvia Shoham serves as Independent Director at Kamada Ltd. He has served on our board of directors since May 2007 and is an independent director within the meaning of the Companies Law. Mr. Shoham is a member of the board of directors of Shachak Co., a private real estate company. Mr. Shoham has extensive experience as a financial consultant for companies in various industry sectors, including managing a wide range of financial arrangements and advising businesses on recovery and privatization plans since 2007.
Age | 70 |
Tenure | 17 years |
Professional Marks | MBA |
Phone | (972) 8 9406472 |
Web | www.kamada.com |
Kamada Management Efficiency
Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 17.41 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kamada has a current ratio of 6.72, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Kamada until it has trouble settling it off, either with new capital or with free cash flow. So, Kamada's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kamada sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kamada to invest in growth at high rates of return. When we think about Kamada's use of debt, we should always consider it together with cash and equity.
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 408 people. Kamada (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 355 people. Management Performance
Return On Equity | -0.058 | |||
Return On Asset | -0.0023 |
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pnina Strauss, Vice President - Inhalation programs & IP | ||
Itzhak Krinsky, Director | ||
Lilach Topilsky, Chairman of the Board | ||
Ari Shamiss, Director | ||
Barak Bashari, Vice President - Operations | ||
Eran Schenker, Vice President - Medical Director | ||
Tuvia Shoham, Independent Director | ||
Eran Nir, Chief Officer | ||
Hanni Neheman, VP Sales | ||
Michal Stein, Vice President and Medical Director for Immunology | ||
Ariella Raban, VP HR | ||
Shani Dotan, Vice President of Human Resources | ||
Liliana Bar, VP of RandD | ||
Yael Brenner, Vice President - Quality | ||
Abraham Havron, Independent Director | ||
Asaf Frumerman, Director | ||
Ruth Wolfson, Senior Vice President - Scientific Affairs | ||
Shmuel Rubinstein, Director | ||
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases | ||
Jon Knight, VP Operations | ||
Michael Berelowitz, Director | ||
David Tsur, Co-Founder and Deputy Executive Chairman | ||
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D | ||
Leon Recanati, Chairman of the Board | ||
Gil Efron, CFO, Principal Accounting Officer and Deputy CEO | ||
Jonathan Hahn, Director | ||
Eran Schenkar, Vice President - Medical Director | ||
Gwen Melincoff, Director | ||
Chaime Orlev, Chief Financial Officer | ||
Michal Ayalon, Vice President - Research & Development | ||
Yifat Esq, Gen Legal | ||
Amir London, Chief Executive Officer | ||
Estery GilozRan, Independent Director | ||
Reuven Behar, Director | ||
Eitan Kyiet, Vice President - Business Development | ||
Ziv Kop, Director |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.058 | |||
Return On Asset | -0.0023 | |||
Profit Margin | (0.09) % | |||
Operating Margin | (0.01) % | |||
Current Valuation | 636.38 M | |||
Shares Outstanding | 44.8 M | |||
Shares Owned By Insiders | 18.50 % | |||
Shares Owned By Institutions | 32.04 % | |||
Price To Book | 1.13 X | |||
Price To Sales | 5.37 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Kamada Stock analysis
When running Kamada's price analysis, check to measure Kamada's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kamada is operating at the current time. Most of Kamada's value examination focuses on studying past and present price action to predict the probability of Kamada's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kamada's price. Additionally, you may evaluate how the addition of Kamada to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |